Kornimate/medical-research-clean huggingface dataset:
limit early adiposity rebound in children

Conditions: Childhood Obesity; Life Style; Intestinal Microbiome

Summary: childhood obesity is a strong predictor of adult obesity with health and economic consequences for the individual and society. adiposity rebound (ar) is a rise in the body mass index occurring between 3-7 years. early adiposity rebound (ear) occurs at a median age of 2 years and is a risk factor for later obesity. events happening in "the first 1,000 days" play a role in obesity development. one of the key elements in this crucial time window is the gut microbiome, a highly dynamic organ that is sensitive to environmental exposure being linked to obesity development. prenatal (dietary/lifestyle maternal factors and environmental exposure) and postnatal determinants (the type of feeding, sleep patterns, speed of growth) and environmental obesogenic pollutants may influence the infant microbial colonization, thus increasing the risk of ear onset. limit will holistically identify the longitudinal interplay between the intestinal microbiome and infant/maternal nutritional and lifestyle habits, environmental factors exposure and anthropometric measurements, in children with ar vs ear, driving new mechanistic insights to create an ear predictive model. the study will evaluate a group of 150 mother-infant pairs, during the first four years of life at different follow-up.


Eligibility criteria:
* inclusion criteria: i) infants of both sexes born to vaginal/caesarean delivery; ii) gestational age: 37-42 weeks; iii) italian-speaking parent; iv) 7 ability of the parent/guardian to give informed consent; v) ability of the mother to answer questionnaires. * exclusion criteria: i) infants with genetic/congenital diseases; ii) infants selected for another clinical study; iii) infants hospitalized immediately after birth; iv) presence of gestational diabetes; v) presence of hyperthyroidism during pregnancy; vi) parents refusing to sign the informed consent.

Keywords: childhood obesity maternal lifestyle gut microbiome adiposity rebound fetal programming first thousand days pregnancy breastfeeding children nutrition endocrine disruptors chemicals
home-based vs. supervised exercise for people with claudication

Conditions: Intermittent Claudication

Summary: the purpose of this study is to examine the effects of a home-based exercise rehabilitation program compared to a supervised exercise program on intermittent claudication (leg pain or discomfort) and ambulatory function.

this study seeks to 1) compare the changes in ambulatory function, vascular function, and health-related quality of life in patients limited by intermittent claudication following a home-based exercise rehabilitation program, a supervised exercise program, and a light resistance training exercise program; and 2) determine whether changes in walking efficiency, calf muscle circulation, and calf muscle oxygen are the reasons by which both home-based and supervised exercise rehabilitation improve ambulatory function. we hypothesize that a home-based exercise program utilizing new physical activity monitoring technology that can accurately quantify exercise adherence as well as the intensity, duration, and volume of exercise sessions will result in similar changes in ambulatory function, vascular function, and health-related quality of life compared to a standard, supervised exercise program. further, both the home-based and supervised exercise rehabilitation programs will result in greater changes in ambulatory function, vascular function, and health-related quality of life than a light resistance training exercise program. finally, we hypothesize that the changes in walking efficiency, calf muscle circulation, and calf muscle oxygen will each be predictive of improved ambulation following the home-based exercise program as well as the supervised exercise program. the 3-month program will consist of walking 3 times per week, with progressive increases in duration and intensity. the two walking exercise programs will be matched on the estimated caloric expenditure during the training sessions. patients in the control group will perform light resistance training without any walking exercise.

Eligibility criteria:
inclusion criteria: * positive history of intermittent claudication assessed by the san diego claudication questionnaire * exercise limited by intermittent claudication during a screening treadmill test using the gardner protocol * ankle/brachial index (abi) less than 0.90 at rest, which decreases to less than 0.73 immediately following the treadmill exercise test exclusion criteria: * absence of pad (peripheral artery disease) * asymptomatic pad (fontaine stage i) * rest pain due to pad (fontaine stage iii) * tissue loss due to pad (fontaine stage iv) * medical conditions that are contraindicative for exercise according to the american college of sports medicine (e.g., acute myocardial infarction, unstable angina, etc.) * cognitive dysfunction (mini-mental state examination score less than 24)

Keywords: aging gait musculoskeletal disorder therapy peripheral blood vessel disorder muscle function muscle strength quality of life
reduced ability to make decisions: a study that observe differences in patients with fibromyalgia and healthy control

Conditions: Fibromyalgia

Summary: the literature has identified impairments in various cognitive functions, including learning, memory, attention, psychomotor speed, executive function, and working memory. however, only a few studies to date have investigated impairment in the decision-making process. the aim of this study is to evaluate decision-making skills in a group of patients with fibromyalgia and compare these results with a group of healthy controls. specifically, investigators will evaluate four hypotheses: 1. patients with fibromyalgia may show disadvantageous decision-making in contexts of emotional decision-making and may persevere more in their wrong choices. for this reason, investigators hypothesize that patients with fibromyalgia will more frequently choose the disadvantageous decks than the healthy control group in the iowa gambling task. 2. secondly, investigators hypothesize that patients with fibromyalgia need more time to make their choice. consistent with this hypothesis, researchers expect to find significant differences in the average time taken by the participant to make a choice in the iowa gambling task. 3. the third hypothesis is that patients with fibromyalgia may have greater difficulty inhibiting automatic responses, which may lead to longer reaction times in the stroop task. investigators also hypothesize that stimuli with negative emotional valence (related to the typical pain experience in fibromyalgia) may have a greater effect on patients with fibromyalgia than on healthy controls (longer reaction time in the emotional stroop task compared to healthy controls). 4. finally, investigators hypothesize that anxiety, depression, sleep quality, pain, decision-making style and social support may be related to worse performance in ability-based tasks.


Eligibility criteria:
inclusion criteria: * fibromyalgia syndrome (confirmed by a medical diagnosis); * able to understand english, dutch or french; * signed an informed consent. exclusion criteria: * other diagnoses (osteoarthritis, rheumatoid arthritis, post-cancer pain, as well as patients with primary psychiatric/neurological conditions or psychopathological disorders); * history of substance abuse or pathological gambling; * color blindness; * not have pain currently or have a recent history of pain (only for healty control group).

Keywords: fibromyalgia decision making stroop task iowa gambling task
probiotics in irritable bowel syndrome

Conditions: Irritable Bowel Syndrome

Summary: probiotics are defined as 'mono- or mixed cultures of live micro-organisms which, when applied to animal or man, beneficially affect the host by improving the properties of the indigenous flora'. certain probiotics possess potent antibacterial and antiviral properties. probiotic antibacterial activity may derive from the direct secretion of bacteriocins, the elaboration of proteases directed against bacterial toxins or through their ability to adhere to epithelial cells and thus exclude pathogens. the antiviral properties of some probiotic organisms, including the stimulation of interferon production, together with the well-documented efficacy of certain probiotics in the therapy of rotavirus diarrhea suggests the potential for a role for these agents in pi-ibs. the efficacy of some probiotics in preferentially relieving 'gas-related' symptoms may be related to qualitative changes in the colonic flora, as described earlier, or through the suppression of small intestinal bacterial overgrowth (sibo) , as there are reports of efficacy of probiotics in sibo. the aim of the proposed study is to investigate whether the probiotic preparation "co biotic" can change the composition of fecal bile acids, fatty acids and bacterial composition, and whether such changes, if they occur, are correlated to a change in the symptoms of patients with ibs. materials and methods: patients diagnosed as having ibs by the rome iii criteria will be included in the study. study subjects will be interviewed by a physician who will asses the diagnosis of ibs according to the rome iii criteria. subjects will sign an informed consent and fill an ibs questionnaire and a health related quality of life questionnaire, a fecal sample will be obtained the subject will receive the probiotic product in a dose of 2 tablets/day, or a placebo containing all the active ingredients in the probiotic capsule, besides the bacteria, for 4 weeks. they will then enter a washout period of 2 weeks in which they will not receive anything, and then another 4 weeks in which they will receive the probiotic product in a dose of 2 tablets/day, or a placebo. patients will be randomized so that they will receive the study drug for 4 weeks and the placebo for 4 weeks, in a double-blinded fashion. thus each patient will be his own control.


Eligibility criteria:
inclusion criteria: * ibs by rome iii criteria exclusion criteria: * other gi disease

Keywords: irritable bowel syndrome probiotics
irofulven in treating patients with stage ivb or recurrent cervical cancer

Conditions: Cervical Cancer

Summary: rationale: drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. purpose: phase ii trial to study the effectiveness of irofulven in treating patients who have stage ivb or recurrent cervical cancer.

objectives: i. evaluate the efficacy of 6-hydroxymethylacylfulvene in patients with stage ivb or recurrent cervical carcinoma. ii. determine the safety of this drug in this patient population. outline: patients receive 6-hydroxymethylacylfulvene iv over 5 minutes daily for 5 consecutive days. treatment continues every 28 days in the absence of unacceptable toxicity or disease progression. projected accrual: a total of 12-37 patients will be accrued for this study within 6-19 months.

Eligibility criteria:
disease characteristics: histologically confirmed primary metastatic (stage ivb) or recurrent cervical carcinoma not amenable to curative therapy squamous adenocarcinoma adenosquamous bidimensionally measurable disease no active brain metastases patient characteristics: age: not specified performance status: karnofsky 70-100% life expectancy: not specified hematopoietic: absolute neutrophil count at least 1,500/mm3 platelet count at least 100,000/mm3 hepatic: bilirubin normal alt/ast no greater than 2.5 times upper limit of normal (uln) renal: creatinine no greater than 1.5 times uln (1.95 mg/dl at mskcc) or creatinine clearance at least 50 ml/min cardiovascular: no new york heart association class iii or iv congestive heart failure no ecg evidence of acute ischemia no significant conduction abnormality (e.g., bifascicular block, 2nd or 3rd degree av blocks) other: not pregnant or nursing negative pregnancy test fertile patients must use effective contraception no other malignancy within the past 5 years and deemed low risk for recurrence no other concurrent clinical circumstances that would compromise safety or integrity of trial prior concurrent therapy: prior multimodality therapy at diagnosis allowed (i.e., concurrent chemotherapy and radiotherapy, neoadjuvant chemotherapy followed by surgery and/or radiotherapy, adjuvant chemotherapy and/or radiotherapy following surgery, or adjuvant chemotherapy following radiotherapy) biologic therapy: not specified chemotherapy: no prior chemotherapy for metastatic or recurrent disease endocrine therapy: not specified radiotherapy: at least 4 weeks since prior radiotherapy surgery: at least 4 weeks since prior major surgery

Keywords: recurrent cervical cancer stage ivb cervical cancer cervical squamous cell carcinoma cervical adenocarcinoma cervical adenosquamous cell carcinoma
double-blind trial of miglitol in type 2 diabetic patients with insulin treatment

Conditions: Type 2 Diabetes Mellitus

Summary: the purpose of this study is evaluate the clinical efficacy and safety of miglitol in patients with type2 diabetes mellitus with treated insulin.


Eligibility criteria:
inclusion criteria: * type2 diabetes * criteria of postprandial plasma glucose and hba1c are met exclusion criteria: * type1 diabetes * patients with antidiabetic drugs * the other exclusion criteria are met

Keywords: alpha-glucosidase inhibitor,insulin
diffusion of use of low molecular weight heparin for thrombosis on the medicine services

Conditions: Thrombosis

Summary: the purpose of this research is to gain insight into the way in which physicians adopt new practice techniques. in particular, we are interested in how medical innovations diffuse throughout social networks. we wish to examine the diffusion of low molecular weight heparin (lmwh) use for deep vein thrombosis (dvt) throughout the social network of general internal medicine interns, residents, and attendings at the university of chicago hospital. in numerous clinical trials, lmwh has been demonstrated to be as effective as unfractionated heparin as a bridge to long-term anticoagulation therapy with coumadin, with the added benefit of early discharge from the hospital with easy dosing, no need for monitoring, and home therapy. a dvt critical pathway was established at the u of c in 1998, and lmwh was used off-label for that purpose beginning in 1997. however, it is unclear how quickly the use of lmwh was adopted by the physicians on the general medicine services, or whether there exists a pattern for this adoption.

the design of our study is retrospective in nature. we are interested primarily in the use of lmwh in patients admitted to the general medicine services between january 1, 1997 and february 1, 2001 with a primary and secondary diagnosis related to venous thromboembolism, including specific icd-9 codes. using a data abstraction form, we gather the following information: 1) patient demographics, 2) identity of the attending, resident, and interns caring for the patient, 3) whether the patient had any absolute or relative contraindications for receiving lmwh, as delineated by the dvt critical pathway, including insurance status and 4)how the patient was treated for his/her condition. to examine whether the identity of the primary care physician affects whether lmwh is given, we also collect the name of the primary care physician if it is listed on the chart.

Eligibility criteria:
inclusion criteria: * patients admitted to general medicine services with a primary or secondary diagnosis related to venous thromboembolism exclusion criteria: * non-general medicine services patients

Keywords: thrombosis low molecular weight heparin
effects of resistin on neutrophil function

Conditions: Inflammation

Summary: to assess the effect of resistin on neutrophil migration and intracellular bacterial killing


Eligibility criteria:
inclusion criteria: * age ≥ 18 * gender: male or female exclusion criteria * adults who are unable to provide informed consent themselves * history of chronic kidney disease as defined by estimated glomerular filtration rate (gfr) \<60 ml/min prior to cardiogenic shock * patients with hematologic malignancies * pregnant women * patient/surrogate is not fluent in english * long-term immunosuppressive therapy * prisoner * patients on pre-existing continuous reno-renal therapy (crrt) or intermittent hemodialysis (ihd
metabolically normal and metabolically abnormal obesity

Conditions: Obesity; Metabolic Syndrome

Summary: the purpose of this study is to learn more about why some obese persons are resistant to developing obesity-related metabolic diseases (such as diabetes and cardiovascular disease), while others are prone to developing these conditions. we will do this by studying obese persons before and after a 5% body weight gain. subjects will be asked to increase their current diet for a period of 8-12 weeks in order to increase their current body weight by 5%. each will then be asked to maintain this weight increase for 3 weeks. we will monitor subjects throughout this time period with weekly medical evaluations. at the completion of the study, we will provide each subject with a 6-month weight loss program.


Eligibility criteria:
inclusion criteria: * obese subjects (bmi 30.0 - 39.9 kg/m2) * sedentary subjects (exercise less than 1 hr/wk) exclusion criteria: * pregnant or lactating women * michigan alcohol screening test score ≥4 * active or previous history of liver disease * active or previous history of diabetes * history of alcohol abuse, or currently consuming ≥20 g alcohol/day * severe hypertriglyceridemia (\>300 mg/dl) * smoke tobacco * take medication that might confound the study results

Keywords: obesity metabolism cardiovascular metabolic syndrome
the avelle® negative pressure wound therapy system on chronic wounds

Conditions: Diabetic Foot Ulcer; Venous Leg Ulcer

Summary: this study seeks to demonstrate the performance of negative pressure wound therapy on chronic wounds such as diabetic foot ulcers and venous leg ulcers.

this study seeks to demonstrate the performance of negative pressure wound therapy on chronic wounds such as diabetic foot ulcers and venous leg ulcers. the primary objective of the study is to demonstrate the performance and safety of avelle negative pressure wound therapy on wound and wound fluid management when used in accordance with the instructions for use. participation in the study is anticipated to be two weeks. the avelle™ npwt system will be used for two weeks and participants will be seen for study visits during this time. study participants will need to visit the doctor's office up to five times and, at a minimum, will be required to see the health care provider three times, dependent on the condition of the wound. each visit is anticipated to last for approximately 45 to 60 minutes.

Eligibility criteria:
inclusion criteria: * venous insufficiency as defined by ceap classification of c6 or c6r or diabetic foot ulcer * stalled wound/failed treatment in the opinion of the investigator. defined as a wound that has not progressed by more than 30% in the previous 4 weeks * 1 qualifying wound which is amenable to npwt * reliable and available for follow-up * low to moderate exudate * able to tolerate negative pressure * \>18 years old at the time of consent * able and willing to provide informed consent exclusion criteria: * known sensitivities or allergies to components of the avelle™ negative pressure wound therapy system * necrotic wounds or wounds with eschar present * wound is too small or too large based on wound dressing (\> 1cm2 and \< 100cm2) * wound depth \>2cm * use of duoderm® gel /petroleum gel/ creams/oil-based products * active treatment for cancer or completed within the last 3 months * severe malnutrition in the opinion of the investigator * visible bone/tendon or exposed articular capsule * exposed blood vessels * clotting disorder * malignant wounds * systemic infection * untreated osteomyelitis * patients with hba1c greater than 9 on day 0 (test to be performed within last 3 months) * wounds greater than 12 months old * previous failed npwt within last 6 weeks on the qualifying wound * active pregnancy * chronic kidney disease score of 5

Keywords: negative pressure wound therapy ulcer
35kda hyaluronan fragment treatment of colorectal and rectal cancer

Conditions: Cancer Pain

Summary: ha35 (bioactive ha or b-ha or ha35) have good tissue permeability (b-ha injection, ministry of health, registration number l20200708mp07707). ha35 might not lose ha's bioactivities of binding to a variety of hyaluronan's binding proteins or receptors, including the analgesic and anticancer effects of hyaluronan, therefore being named bioactive ha or b-ha (10) (b-ha injection, ministry of health, registration number l20200708mp07707).

the previous study has shown that naked mole rat who has high tissue content of hyaluronan and its fragments is insensitive to pain. the previous study has also shown that hyaluronan modulates pain-regulated trpv1 channel opening, reducing peripheral nociceptor activity and pain. the previous study has again shown that local injection of 35kda hyaluronan fragment ha35 is effective in treating inflammatory and neuropathic pain. this study employs freshly made ha35 injection for treatment of pain associated with radiotherapy for treatment of colorectal and rectal cancer. a numerical rating scale from 0 to 10 was used to assess the pain after 1 hour, 3 hours, 24 hours, 48 hours and 72 hours of the injection.

Eligibility criteria:
inclusion criteria: * all patients had different degrees of metastasis of the cancers, including bone metastasis. * all patients undergo targeted radiotherapy shortly before this study. * all the patient volunteers included in this study were allowed to use antibiotic compounds on and off during the treatment in order to prevent possible infection associated with the cancers for ethnic consideration. * the included patients were aged 48 to 60 years. exclusion criteria: * can not independently determine the level of pain. * severe bleeding and severe inflammation

Keywords: 35kda hyaluronan fragment pain colorectal cancer rectal cancer
integrated treatment in fnd (functional neurological disorders)

Conditions: Functional Neurological Disorder

Summary: the project will investigate the effectiveness of patient-centered integrated treatment. the correlations between physiotherapy indices, non-invasive brain stimulation, connectivity and psychological support will be analyzed.

at the time of recruitment (t0) a multidimensional evaluation will be performed consisting of clinical, neuropsychological, neurophysiological, mri, data obtained from peripheral blood sampling (10ml). after completing the program (12 weeks), the effect will be assessed according to objectives (t1). the study will also include a follow-up evaluation after 6 months (t2) and 12 months (t3) from the beginning of the treatment to evaluate the persistence of the beneficial effects after some time.

Eligibility criteria:
inclusion criteria: * ability to provide written informed consent * diagnosis of functional neurological disorder of movement clinically established according to dsm-5 criteria * age between 18 and 65 years (inclusive) * ability to participate in the study protocol exclusion criteria: * inability to provide written informed consent * pregnant women * in case of use of non-invasive brain stimulation techniques: the subjects must not present any of the contraindications specific to this method (for further specifications see the "methods" and the "stimulation evaluation questionnaire" attached to this proposal) * presence of unstable clinical conditions or infections * in the case of the use of non-invasive brain stimulation techniques: concomitant use of drugs that can alter the transmission and synaptic plasticity (cannabinoids, l-dopa, antiepileptics, nicotine, baclofen, selective serotonin reuptake inhibitors (ssri), botulinum toxin) * inability to support physiotherapy or psychotherapy sessions

Keywords: fnd physiotherapy psychotherapy non-invasive brain stimulation